Ascendis Pharma A/S Target Price

Where could ASND trade next? Consensus target price: $320.

Get informed when a big investor buys or sells

+ Follow

Share Price

$230.7

Average Target Price

$315.47

36.7% upside

15 analysts in the last 4 months

High: $345 | Low: $273

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-09-16	UBS	$344	49.1% upside
2026-09-15	Raymond JamesMartin Auster	$287	24.4% upside
2026-09-10	H.C. Wainwright	$344	49.1% upside
2026-09-01	OppenheimerLeland Gershell	$312	35.2% upside
2026-09-01	Morgan StanleyMaxwell Skor	$273	18.3% upside
2026-08-31	Jefferies	$330	43% upside
2026-08-31	Stifel Nicolaus	$326	41.3% upside
2026-08-31	UBS	$345	49.5% upside
2026-08-27	H.C. Wainwright	$345	49.5% upside
2026-08-18	BMO Capital	$319	38.3% upside
2026-08-14	RBC CapitalLuca Issi	$290	25.7% upside
2026-08-14	Barclays	$329	42.6% upside
2026-08-13	JefferiesKelly Shi	$333	44.3% upside
2026-07-23	Morgan Stanley	$275	19.2% upside
2026-07-07	RBC Capital	$280	21.4% upside
2026-05-15	Evercore ISI	$329	42.6% upside
2026-05-11	Barclays	$345	49.5% upside
2026-05-08	Wells Fargo	$326	41.3% upside
2026-03-05	Jefferies	$262	13.6% upside
2026-03-04	Stifel NicolausAlex Thompson	$332	43.9% upside
2026-03-02	Wolfe ResearchKalpit Patel	$260	12.7% upside
2026-03-02	Cantor FitzgeraldLi Watsek	$300	30% upside
2026-03-02	Evercore ISIJosh Schimmer	$324	40.4% upside
2026-03-02	Goldman SachsPaul Choi	$255	10.5% upside
2026-02-12	Wedbush	$273	18.3% upside
2026-02-12	Oppenheimer	$262	13.6% upside
2026-02-12	Stifel NicolausAlex Thompson	$325	40.9% upside
2026-02-12	Morgan StanleyMaxwell Skor	$256	11% upside
2026-01-27	BarclaysEliana Merle	$342	48.2% upside
2026-01-20	RBC Capital	$250	8.4% upside
2026-01-20	Wells FargoDerek Archila	$330	43% upside
2026-01-09	Wells Fargo	$322	39.6% upside
2025-12-11	Stifel NicolausAlex Thompson	$256	11% upside
2025-10-13	Cantor FitzgeraldLi Watsek	$254	10.1% upside
2025-08-08	RBC CapitalLuca Issi	$230	0.3% downside
2025-02-18	Morgan Stanley	$180	22% downside
2024-09-23	Bank of America SecuritiesTazeen Ahmad	$191	17.2% downside
2024-09-17	Evercore ISIGavin Clark-Gartner	$205	11.1% downside
2024-09-17	OppenheimerLeland Gershell	$190	17.6% downside
2024-09-17	CitigroupDavid Lebowitz	$207	10.3% downside
2024-09-17	Wells FargoDerek Archila	$289	25.3% upside
2024-09-16	Bank of America SecuritiesTazeen Ahmad	$175	24.1% downside
2024-09-16	Goldman SachsPaul Choi	$200	13.3% downside
2024-09-13	CitigroupDavid Lebowitz	$178	22.8% downside
2024-09-05	OppenheimerLeland Gershell	$180	22% downside
2024-08-13	JefferiesKelly Shi	$196	15% downside
2024-05-30	Stifel NicolausAlex Thompson	$200	13.3% downside
2024-05-15	Morgan StanleyVikram Purohit	$140	39.3% downside
2024-03-14	Evercore ISIJosh Schimmer	$191	17.2% downside
2023-01-03	Wells Fargo	$177	23.3% downside

Ascendis Pharma A/S (ASND) FAQ

The latest target price for ASND is $320. Investors often review this figure alongside Ascendis Pharma A/S's historical trend and sector peers before judging valuation or financial health.

Ascendis Pharma A/S trades near $230.7 while the consensus target sits at $320 (36.7% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting ASND's target price ($320), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Ascendis Pharma A/S's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.